The American Thyroid Association (ATA) has unveiled new guidelines designed to enhance the management of adult patients with differentiated thyroid cancer (DTC), the most common form of thyroid cancer. Published in the peer-reviewed journal Thyroid®, these guidelines aim to establish a new standard of care for thyroid cancer patients.
Developed by an ATA task force, the guidelines were led by Co-Chairs Dr. Matthew Ringel from The Ohio State University College of Medicine and Comprehensive Cancer Center, and Dr. Julie Ann Sosa from the University of California San Francisco. The task force incorporated input from a diverse group of stakeholders, including specialists across various fields of thyroid cancer care, a patient advocate, and an expert in systematic reviews and meta-analyses. ATA President Dr. Jacqueline Jonklaas praised the task force, stating,
“ATA leadership is grateful to the task force members, ably led by Drs. Ringel and Sosa, for this superlative clinical practice guideline that I believe will help set the standard of care for future generations of patients with thyroid cancer.”
Comprehensive Guidelines for Thyroid Cancer Management
The newly revised guidelines cover the entire spectrum of thyroid cancer management, starting from the initial diagnosis. They provide detailed recommendations on staging and risk assessment, initial treatment decisions, and the evaluation of treatment responses. Additionally, the guidelines offer insights into monitoring strategies, diagnostic testing, and subsequent therapies, all based on the strength of evidence and consideration of side effects and outcomes.
Patient-reported outcomes and thyroid cancer survivorship are also emphasized, along with areas identified as needing further high-quality research. Dr. Christopher McCabe, ATA Secretary and Chief Operating Officer, highlighted the significance of these guidelines, stating,
“This thyroid cancer guideline continues the ATA’s leadership in providing high quality and evidence-based guidelines which provide thoughtful guidance to clinicians taking care of patients with thyroid cancer.”
About the Journal Thyroid®
Thyroid®, the official journal of the American Thyroid Association, is a leading peer-reviewed publication that offers open access options and is available both online and in print. Under the leadership of Editor-in-Chief Dr. Anna M. Sawka from the University of Toronto, the journal publishes original articles and reviews that reflect the rapid advancements in thyroid physiology and pathology. These range from molecular biology to clinical management of thyroid disorders.
The journal’s comprehensive program includes Clinical Thyroidology®, an abstract and commentary publication led by Editor-in-Chief Dr. Trevor E. Angell, and the innovative videojournal companion, VideoEndocrinology, led by Editor Dr. Catherine F. Sinclair. Both provide valuable resources for clinicians and researchers.
The Role of the American Thyroid Association
The American Thyroid Association is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery, and advocacy. With over 1,800 members from 43 countries, the ATA fosters a collaborative and diverse community. It promotes thyroid awareness through resources like Clinical Thyroidology® for the Public, which summarizes research for patients and families, and offers extensive information on thyroid disease and cancer in both English and Spanish.
The ATA’s website, www.thyroid.org, serves as a reliable clinical resource for patients and the public seeking trustworthy thyroid-related information.
Publishing Partner: Mary Ann Liebert, Inc.
Mary Ann Liebert, Inc., a Sage Company, is a global media entity committed to publishing impactful peer-reviewed research across biotechnology, life sciences, specialized clinical medicine, public health, policy, and technology. Since its inception in 1980, the company has been a pivotal source of critical insights and content that empower researchers and clinicians to drive innovation and discovery worldwide.
The release of these new guidelines by the ATA represents a significant step forward in the care and management of thyroid cancer, promising to improve outcomes for patients and set a benchmark for future research and clinical practice.
